Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653864 | 0.86 | ALDH1A1 (0.46) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL4082038 | 0.85 | ALDH1A1 (0.64) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL7618433 | 0.84 | USP2 (0.55) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL6484412 | 0.83 | LMNA (0.68) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL15220027 | 0.83 | LMNA (0.50) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL11913777 | 0.83 | LMNA (0.50) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL11400795 | 0.81 | LMNA (0.65) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL18419074 | 0.81 | LMNA (0.65) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL12354861 | 0.81 | LMNA (0.65) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL3084957 | 0.81 | LMNA (0.65) | ALDH1A1USP2TSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4034107-A1 | JAK INHIBITORS | Vimalan Biosciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| CN-101889017-A | Alkoxy compounds for the treatment of diseases | ACUCELA INC | 2010-11-17 | — | — | CN | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| CN-1183778-A | Quinolinecarboxylic acid derivs. | HOKURIKU PHARMACEUTICAL (JP) | 1998-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | ALDH1A1 2035/4885USP2 3697/4885TSHR 123/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 133/4885USP2 3473/4885TSHR 2971/4885 |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | ALDH1A1 600/4885USP2 788/4885TSHR 3077/4885 |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | ALDH1A1 4142/4885USP2 3930/4885TSHR 3487/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.